Intralesional 5-fluorouracil in keloid treatment: a systematic review

Acta Derm Venereol. 2015 Sep;95(7):778-82. doi: 10.2340/00015555-2106.

Abstract

In the 1990s, 5-flourouracil (5-FU) was introduced as a treatment for keloids; however, there is still no consensus on its use. In order to guide clinical practice, a systematic review of the clinical evidence on the effectiveness of 5-FU in keloid treatment was carried out. Eight databases were searched on 10 September 2014 using the terms "keloid" and "5-FU", together with all synonyms of these terms. Two reviewers selected original research reports using 5-FU alone or combined with a maximum of 2 other therapies. Eighteen papers were found that reported either on intralesional 5-FU alone, or on 5-FU combined with triamcinolone acetonide (TAC:5-FU) or excision, including 482 patients. 5-FU treatment was effective in 45-96% of patients, but only TAC:5-FU may perform better than TAC alone. Due to a poor level of evidence, further research should establish the superiority of repeated intralesional TAC:5-FU injections over TAC alone with several doses and injection schedules.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Dermatologic Agents / administration & dosage*
  • Dermatologic Agents / adverse effects
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Fluorouracil / administration & dosage*
  • Fluorouracil / adverse effects
  • Glucocorticoids / administration & dosage
  • Humans
  • Injections, Intralesional
  • Keloid / diagnosis
  • Keloid / drug therapy*
  • Skin / drug effects*
  • Skin / pathology
  • Treatment Outcome
  • Triamcinolone Acetonide / administration & dosage

Substances

  • Dermatologic Agents
  • Glucocorticoids
  • Triamcinolone Acetonide
  • Fluorouracil